ProCE Banner Activity

Anemia of CKD: Emerging Treatments

Clinical Thought

Here&rsquo s my take on a promising new class of agents in development to treat anemia of CKD, their distinct advantages and disadvantages, and their potential place in therapy, if approved.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.

Share

Faculty

Jay Wish

Jay Wish, MD

Professor of Clinical Medicine
Department of Medicine
Indiana University School of Medicine
Chief Medical Officer for Outpatient Dialysis
Division of Nephrology
Indiana University Health
Indianapolis, Indiana

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

GlaxoSmithKline

Faculty Disclosure

Primary Author

Jay Wish, MD

Professor of Clinical Medicine
Department of Medicine
Indiana University School of Medicine
Chief Medical Officer for Outpatient Dialysis
Division of Nephrology
Indiana University Health
Indianapolis, Indiana

Jay Wish, MD: consultant/advisor/speaker: Akebia, Amgen, AstraZeneca, CSL Behring, FibroGen, Otsuka, Rockwell Medical, Vifor Pharma; independent contractor: GlaxoSmithKline.